Rigel Pharmaceuticals News (NASDAQ:RIGL)
| Latest Rigel Pharmaceuticals News Headlines | | Date | Time | Source | | | 07/03/2008 | 7:30AM | PRNUS | Rigel to Present at Collins Stewart Growth Conference
SAN FRANCISCO, July 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul Rodriguez, Rigel's executive vice president and chief operating officer, will present a company overview at the Fourth Annual Collins Stewart Growth Conference on Tuesday, July 8, 2008 at 11:30 a.m. EDT... More...>> |
| 06/18/2008 | 7:30AM | PRNUS | Rigel to Present at Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will be presenting a company overview at the Jefferies 2nd Annual Healthcare Conference in New York on Thursday, June 26 at... More...>> |
| 06/12/2008 | 7:30AM | PRNUS | Rigel Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis
TASKI 2 and TASKI 3 Trials Launch Globally
SOUTH SAN FRANCISCO, Calif., June 12 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the initiation of two Phase 2b clinical trials of its orally bioavailable Syk inhibitor, R788 (fostamatinib disodium), in patients with rheumatoid arthritis... More...>> |
| 06/05/2008 | 7:30AM | PRNUS | Rigel to Present at the Needham Biotechnology and Medical Technology Conference
SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that James M. Gower, Rigel's chairman and chief executive officer, will be presenting a company overview at the Seventh Annual Needham Biotechnology and Medical Technology Conference on Thursday, June... More...>> |
| 06/02/2008 | 5:10PM | PRNUS | Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will host a conference call with simultaneous webcast to discuss the preliminary results of its Phase 2 clinical study of R788, a novel, oral Syk kinase inhibitor, in patients with B-cell non-Hodgkin's... More...>> |
| 05/22/2008 | 6:00AM | PRNUS | VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors
Rigel Pharmaceuticals CMO to Add Valuable Clinical Development Expertise
SAN DIEGO, May 22 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today... More...>> |
| 05/06/2008 | 7:30AM | PRNUS | Rigel Announces First Quarter 2008 Financial Results
SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today reported financial results for the first quarter ended March 31, 2008.
During the first quarter of 2008, Rigel reported a net loss of $27.3 million, or $0.79 per share, compared to a net loss of $17.1 million... More...>> |
| 04/29/2008 | 7:30AM | PRNUS | Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies
Lead drug candidate may help patients with Systemic Lupus Erythematosus (SLE)
SOUTH SAN FRANCISCO, Calif., April 29 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced today that its lead product candidate, R788, has successfully treated lupus prone mice and significantly improved their survival... More...>> |
| 04/08/2008 | 7:30AM | PRNUS | Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model
Research To Be Presented at American Association of Immunologists Meeting
SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mellitus, according to research... More...>> |
| 03/27/2008 | 7:30AM | PRNUS | Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
SOUTH SAN FRANCISCO, Calif., March 27 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Raul R. Rodriguez, the company's executive vice president and chief operating officer, is scheduled to present a company overview at the 8th Annual Fortis Biotech Conference in London, England... More...>> |
| 03/13/2008 | 7:30AM | PRNUS | Rigel Announces Participation in Upcoming Investor and Partnering Conferences
SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 11th Annual Lehman Brothers Global Healthcare Conference in Miami, Florida... More...>> |
| 02/26/2008 | 7:30AM | PRNUS | Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
SOUTH SAN FRANCISCO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has named Daniel B. Magilavy, M.D. vice president of clinical research. In this newly created position, Dr. Magilavy will be responsible for the direction and oversight of Rigel's clinical... More...>> |
| 02/12/2008 | 7:30AM | PRNUS | Rigel Announces Fourth Quarter and Year End 2007 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced financial results for the fourth quarter and year ended December 31, 2007.
For the fourth quarter of 2007, Rigel reported a net loss of $19.0 million, or $0.61 per share, compared to a net loss of... More...>> |
| 02/06/2008 | 7:30AM | PRNUS | Rigel to Present at BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the BIO CEO & Investor Conference 2008 in New York on Monday, February 11 at 11:45... More...>> |
| 01/31/2008 | 8:33PM | PRNUS | Rigel Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the pricing of its public offering of 5,000,000 shares of common stock at a price of $27.00 per share. All of the shares are being offered by Rigel. The underwriters have an option to purchase up... More...>> |
| 01/24/2008 | 4:14PM | PRNUS | Rigel Announces Offering of 4,000,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will initiate an offering of 4,000,000 shares of common stock pursuant to an automatically effective shelf registration statement on file with the Securities And Exchange Commission. It is... More...>> |
| 01/15/2008 | 7:30AM | PRNUS | Rigel to Present Programs at Four Upcoming Scientific Conferences
SOUTH SAN FRANCISCO, Calif., Jan. 15 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will present at four upcoming scientific conferences. Details are as follows:
Keystone Symposia: Molecular Mechanisms of Angiogenesis in Development and Disease -- Vancouver, BC
Date:... More...>> |
| 01/09/2008 | 7:30AM | PRNUS | Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
SOUTH SAN FRANCISCO, Calif., Jan. 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced today that it has begun enrolling patients in a Phase 1 study to evaluate the safety and tolerability of R348, an orally available, potent inhibitor of Janus Kinase 3 (JAK3), as a potential treatment for... More...>> |
| 12/13/2007 | 7:30AM | PRNUS | Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Achieves Statistically Significant ACR20, ACR50 & ACR70 Results
SOUTH SAN FRANCICSO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that its oral syk kinase inhibitor, R788 (tamatinib fosdium), has demonstrated statistically significant results in treating Rheumatoid... More...>> |
| 12/06/2007 | 7:30AM | PRNUS | Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that its corporate partner, Pfizer (NYSE:PFE), has begun a Phase 1 clinical trial of an inhaled formulation of Rigel's small molecule syk kinase inhibitor, R343, for the treatment of allergic asthma... More...>> |
|
|
|